<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172571</url>
  </required_header>
  <id_info>
    <org_study_id>AK105-203</org_study_id>
    <nct_id>NCT04172571</nct_id>
  </id_info>
  <brief_title>A Phase II Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>An Open-Label Multi-Center Phase Ib/II Study of the Combination of AK105 and Anlotinib Hydrochloride in the First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akeso Tiancheng, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1
      antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with
      unresectable hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>ORR is the proportion of subjects with CR or PR based on RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events (AEs)</measure>
    <time_frame>From the time of informed consent through 90 days after last dose of AK105</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>PFS is defined as the time from the date of first dosing till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>OS is the time from the date of first dosing to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK105</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105</time_frame>
    <description>The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105</time_frame>
    <description>The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AK105 and anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK105</intervention_name>
    <description>Anti-PD-1 antibody; IV infusion, 200 mg Q3W</description>
    <arm_group_label>AK105 and anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off</description>
    <arm_group_label>AK105 and anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent form voluntarily.

          -  Male or female，age over 18 years old (inclusive) and not more than 75 years old
             (inclusive), when signing the ICF.

          -  Expected life expectance ≥ 3 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

          -  Confirmation either by histology unresectable hepatocellular carcinoma..

          -  BCLC stage C, and non-resectable BCLC stage B .

          -  No prior systemic therapy for HCC.

          -  Child-Pugh class A and B (≤7 points).

          -  At least one measurable lesion according to RECIST criteria.

          -  Adequate hematologic and end-organ function.

          -  For women of childbearing potential: agreement to remain abstinent; For men: agreement
             to remain abstinent.

        Exclusion Criteria:

          -  Prior treatment with anti-PD1, anti-PD-L1 or anti-CTLA-4 antibody therapy.

          -  Active ongoing infection requiring therapy.

          -  History of severe hypersensitivity reaction to another monoclonal antibody.

          -  Received any live attenuated vaccine within the last 30 days.

          -  Other malignancy requiring treatment in the prior 5 years with the exception of
             locally treated squamous or basal cell carcinoma.

          -  Pregnant, breast feeding, or planning to become pregnant.

          -  Active or prior documented autoimmune or inflammatory disease with some exceptions.

          -  Central nervous system metastases and/or carcinomatous meningitis.

          -  Medical condition that requires chronic systemic steroid therapy, or any other form of
             immunosuppressive medication.

          -  Co-infection of HBV and HCV.

          -  Inadequately controlled arterial hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shunchang Jiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Bai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoping Jin, PhD</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangfang Jing, MD</last_name>
      <phone>+86-010-66937003</phone>
    </contact>
    <investigator>
      <last_name>Shunchang Jiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Tyrosine Kinase Inhibitor (TKI)</keyword>
  <keyword>Angiogenesis-related kinases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

